Drug Landscape ›
bupivacaine and epinephrine ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 21
Most-reported reactions
Postoperative Wound Complication — 4 reports (19.05%) Skin Desquamation — 4 reports (19.05%) Infusion Site Reaction — 3 reports (14.29%) Necrosis — 2 reports (9.52%) Postoperative Infection — 2 reports (9.52%) Surgical Procedure Repeated — 2 reports (9.52%) Carotid Artery Stenosis — 1 report (4.76%) Ischaemic Stroke — 1 report (4.76%) Medical Device Complication — 1 report (4.76%) Pharmaceutical Product Complaint — 1 report (4.76%)
Source database →
bupivacaine and epinephrine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is bupivacaine and epinephrine approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for bupivacaine and epinephrine in United States?
Mayo Clinic is the originator. The local marketing authorisation holder may differ — check the official source linked above.